Valuation: Cohance Lifesciences Limited

Capitalization 187B 1.98B 1.68B 1.54B 1.45B 2.71B 2.73B 18.24B 7.11B 89.71B 7.42B 7.26B 310B P/E ratio 2026 *
87.8x
P/E ratio 2027 * 59.9x
Enterprise value 185B 1.96B 1.67B 1.52B 1.44B 2.68B 2.71B 18.09B 7.05B 88.95B 7.36B 7.2B 307B EV / Sales 2026 *
7.93x
EV / Sales 2027 * 6.82x
Free-Float
39.87%
Yield 2026 *
-
Yield 2027 * -
1 day+0.69%
1 week+1.02%
Current month+1.02%
1 month+54.08%
3 months+39.97%
6 months-31.01%
Current year-7.64%
1 week 450.8
Extreme 450.8
502.35
1 month 350.1
Extreme 350.1
514.9
Current year 266.7
Extreme 266.7
526.1
1 year 266.7
Extreme 266.7
1,121.15
3 years 266.7
Extreme 266.7
1,360
5 years 266.7
Extreme 266.7
1,360
10 years 87.6
Extreme 87.6
1,360
Manager TitleAgeSince
Director of Finance/CFO 32 2024-01-01
Compliance Officer 48 2026-04-08
Compliance Officer - -
Director TitleAgeSince
Director/Board Member - 2023-09-28
Director/Board Member 68 2023-09-28
Director/Board Member 63 2023-09-28
Change 5d. change 1-year change 3-years change Capi.($)
+0.69%+1.02%-54.70%+2.80% 1.98B
-2.72%-1.54%+29.12%+121.40% 846B
-0.53%-2.58%+43.51%+37.42% 533B
-0.57%-2.44%+9.18%+37.27% 356B
-0.94%-0.97%+22.40%+11.18% 324B
+0.23%-1.24%+30.31%+12.00% 282B
+0.05%-2.19%+24.69%+21.29% 278B
-0.82%-0.70%+46.61%-5.15% 275B
-1.76%+4.42%-34.66%-49.15% 203B
+0.79%+0.57%+24.76%+41.49% 179B
Average -0.56%-0.30%+14.12%+23.06% 327.77B
Weighted average by Cap. -1.05%-1.26%+25.59%+44.20%

Financials

2026 *2027 *
Net sales 23.37B 247M 210M 192M 182M 339M 342M 2.28B 890M 11.22B 928M 909M 38.75B 26.93B 285M 242M 222M 209M 390M 394M 2.63B 1.03B 12.94B 1.07B 1.05B 44.66B
Net income 2.17B 22.96M 19.51M 17.85M 16.85M 31.43M 31.71M 212M 82.56M 1.04B 86.15M 84.34M 3.6B 3.13B 33.11M 28.13M 25.75M 24.3M 45.33M 45.73M 305M 119M 1.5B 124M 122M 5.19B
Net Debt -1.58B -16.73M -14.21M -13M -12.27M -22.9M -23.1M -154M -60.13M -759M -62.75M -61.43M -2.62B -3.03B -32.08M -27.26M -24.94M -23.54M -43.92M -44.3M -296M -115M -1.46B -120M -118M -5.02B
Logo Cohance Lifesciences Limited
Suven Pharmaceuticals Limited is an India-based biopharmaceutical company. The Company is engaged in the business of contract development and manufacturing organization (CDMO). It is primarily engaged in the business of development and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company operates through manufacturing (CRAMS) - bulk drugs & intermediates under contract services products are developed and produced on an exclusive basis under contract manufacturing services. Its geographical segments include India, the USA, Europe, and the Rest of the world. Its manufacturing capabilities for NCEs include real-time formulation development support for adaptive clinical trials and reduced production costs with novel dosage forms that minimize R&D iteration.
Employees
1,212
Date Price Change Volume
26-05-08 488.20 +0.69% 2,338,347
26-05-07 484.85 +0.75% 1,916,847
26-05-06 481.25 +5.97% 14,192,770
26-05-05 454.15 -3.53% 1,437,201
26-05-04 470.75 -2.59% 1,879,134
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
488.20INR
Average target price
477.67INR
Spread / Average Target
-2.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. COHANCE Stock